Healius Limited delivered a significant earnings upgrade in FY 2026, with underlying earnings before interest and tax surging 76.6% to $30.2 million, substantially outperforming the 8.1% growth in EBITDA to $258.6 million. This disproportionate EBIT expansion reveals the real story: disciplined cost management and operational leverage are beginning to materialise after years of sector headwinds. Group revenue grew 2.1% to $1.37 billion, a modest top-line performance that masks meaningful margin expansion beneath the surface.
The earnings acceleration stems from a combination of strategic execution and operational discipline. Cost growth was held to just 0.8% for the full year, with labour costs remaining essentially flat despite inflationary pressures and the Fair Work Commission’s gender undervaluation determination. A labour optimisation program delivered a 5% reduction in full-time equivalent headcount, with the benefits particularly evident in the second half when labour costs fell 2.9%. This suggests management has successfully navigated the difficult trade-off between maintaining service capacity and controlling the cost base, something that has eluded the sector broadly.
Pathology, representing the bulk of group earnings, grew revenue 1.8% to $1.33 billion despite a 1.3% decline in volumes. This reveals the value of Healius’s shift toward revenue quality and pricing power. Average fees per episode increased 4.0%, driven by strong performance in higher-margin segments including Genomic Diagnostics, Public Hospitals, and B2B services. Volumes were impacted by Medicare changes, particularly the July 2025 adjustment to B12 and urine testing criteria, but excluding the loss of two material hospital contracts, underlying volume growth was positive at 0.3%. The second-half turnaround in EBIT, which reached $18.6 million compared to a weaker first half, suggests the margin trajectory is improving as cost initiatives embed.
Agilex Biolabs emerged as a growth engine, with revenue climbing 14.1% to $43.6 million and EBITDA surging 67.2% to $10.7 million. While Agilex remains modest in scale relative to Pathology, the earnings velocity signals that the diversification strategy is working. The business is moving toward profitability at an accelerating pace.
For investors, the results demonstrate that Healius is successfully executing its strategy to offset structural sector challenges through revenue mix improvement and productivity gains. The 2H acceleration in profitability and the embedded nature of the cost savings suggest momentum into FY 2027. Key monitoring points include whether Pathology can maintain pricing discipline amid volume pressures, the trajectory of Agilex’s profitability, and whether labour cost reductions can be sustained without service degradation. This announcement is price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About Healius Limited (ASX: HLS)
Healius Limited is Australia’s second-largest pathology provider, operating a network of pathology laboratories, diagnostic imaging centres, and day hospitals across the country. The company operates through Pathology and Imaging segments, providing medical laboratory services and diagnostic imaging services to patients and healthcare providers. Healius maintains around 2,000 collection sites and nearly 100 pathology laboratories throughout Australia.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
